UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 15, 2004
--------------
DOR BIOPHARMA, INC
---------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-14778 41-1505029
---------- ----------- -----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
1691 MICHIGAN, SUITE 435, MIAMI, FL 33139
------------------------------------ --------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (305) 534-3383
--------------
NOT APPLICABLE
--------------
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
-----------------------------------------
We have completed our sale of securities in a private placement to institutional
investors with gross proceeds of $3.25 million. On March 15, 2004, we issued a
press release with respect thereto, which is attached to this Form 8-K as
Exhibit 99.1 and incorporated herein by reference
Exhibits
99.1 Press Release of DOR BioPharma, Inc regarding the Private
Placement Financing
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DOR BioPharma, Inc.
Date: March 15, 2004 By: /s/Ralph Ellison
-------------- ---------------------------
Ralph Ellison
Chief Executive Officer and
President